Meeting
2013 ASCO Annual Meeting
An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).
Authors
Tom Stinchcombe
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Tom Stinchcombe , Lynette M. Sholl , Xiaofei F. Wang , Lin Gu , Mark A. Socinski , Scott J. Rodig , Marzia Capelletti , Jeffrey Crawford , Martin J. Edelman , Miguel Angel Villalona-Calero , Robert Arthur Kratzke , Everett E. Vokes , Vincent A. Miller , Pasi Antero Janne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
00126581
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8039)
DOI
10.1200/jco.2013.31.15_suppl.8039
Abstract #
8039
Poster Bd #
32C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
First Author: Giuseppe Giaccone
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates